Biogen Idec touted significant growth in its third quarter income and said it is evaluating "strategic options" for its older cancer drug Zevalin that includes a possible sale of the therapy. The growth in revenue--from $596 million a year ago to $703 million this past quarter--was due largely to the return of Tysabri and increased revenue from Rituxan, which has emerged as the "gold standard" in the treatment of rheumatoid arthritis.
- here's a report on Biogen Idec from the Boston Business Journal